2. Academic Validation
  3. Network pharmacology-based exploration of the mechanism of Wenweishu granule in treating chronic atrophic gastritis with spleen-stomach cold deficiency syndrome

Network pharmacology-based exploration of the mechanism of Wenweishu granule in treating chronic atrophic gastritis with spleen-stomach cold deficiency syndrome

  • J Ethnopharmacol. 2025 Apr 9:345:119591. doi: 10.1016/j.jep.2025.119591.
Jia Zheng 1,  Zhiyong Jiao 1,  Xinyu Yang 1,  Qing Ruan 1,  Yuzhe Huang 2,  Cheng Jin 2,  Shuangying Gui 2,  Zihua Xuan 1,  Xiaoyi Jia 3
Affiliations

Affiliations

  • 1 College of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, China; Anhui Province Key Laboratory of Bioactive Natural Products, Hefei, 230012, China.
  • 2 College of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, China; Institute of Pharmaceutics, Anhui Academy of Chinese Medicine, Hefei, Anhui, 230012, China.
  • 3 College of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, China; Anhui Province Key Laboratory of Bioactive Natural Products, Hefei, 230012, China. Electronic address: jiaxy@ahtcm.edu.cn.
PMID: 40054637 DOI: 10.1016/j.jep.2025.119591
Abstract

Ethnopharmacological relevance: Wenweishu (WWS) is a traditional Chinese medicine compound formulated for chronic atrophic gastritis (CAG) treatment by warming the stomach and alleviating pain. However, its pharmacological mechanisms remain underexplored.

Aim of the study: This study investigated the therapeutic effects and potential mechanisms of WWS on CAG with spleen-stomach cold deficiency syndrome (SSCDS).

Methods: To achieve this, an SSCDS-CAG rat model and a human gastric mucosal epithelial cells (GES-1) cell model were established using multi-factor modeling and N-Methyl-N'-nitro-N-nitrosoguanidine (MNNG) induction, respectively. WWS's effects on gastric injury were evaluated through pathology, inflammation, serum biomarkers, and Apoptosis. Additionally, MNNG's effects on GES-1 cells were analyzed. Network pharmacology, involving protein-protein interaction networks, GO/KEGG enrichment, and molecular docking, was employed to predict WWS's potential targets and mechanisms in SSCDS-CAG. Mechanistic insights were further validated using immunohistochemistry, quantitative reverse transcription polymerase chain reaction, and western blotting.

Results: In vivo results showed that WWS alleviated symptoms in SSCDS-CAG rats, lowering symptom scores and improving gastric histopathology. It modulated serum biomarkers and reduced inflammation and Apoptosis in both in vivo and in vitro studies. Network pharmacology results revealed 263 overlapping targets between WWS and SSCDS-CAG, associated with Apoptosis, inflammation, and the PI3K/Akt pathway. Molecular docking revealed strong binding affinity between the core target and active WWS components. In SSCDS-CAG rats and GES-1 cells, WWS inhibited PI3K/Akt phosphorylation, increased PTEN expression, and regulated Bcl-2, Bax, and cleaved Caspase-3 levels.

Conclusion: WWS reduces inflammation and Apoptosis in multi-factor CAG rats and MNNG-induced GES-1 cells by modulating the PTEN/PI3K/Akt signaling pathway and apoptosis-related proteins.

Keywords

Chronic atrophic gastritis; Network pharmacology; PTEN/PI3K/AKT; Spleen-stomach cold deficiency; Wenweishu.

Figures
Products